Presentations featuring MRIdian Linac Technology

Two ASTRO Scientific Session presentations focused on the MRIdian Linac technology, which recently received European CE Mark clearance, and is pending FDA 510(k) clearance and therefore available for non-clinical research use only in the United States. Researchers from Washington University and UCLA highlighted the design and performance of ViewRay's compact Linac-based MRI-guided radiation therapy research system. This next-generation technology from ViewRay utilizes patented magnetic shielding and RF shielding technology that eliminates cross-talk between Linac and MRI components.


"We're pleased with the caliber of clinical data presented at this year's ASTRO meeting by a variety of MRIdian users from around the world, including research on the MRIdian Linac technology," said Chris A. Raanes, president and chief executive officer of ViewRay. "These institutions are demonstrating the real value of MRIdian in terms of performance, capabilities and most importantly patient outcomes."

Industry Expert Theater and In-booth Presentations

ViewRay hosted one of ASTRO's Industry Expert Theater sessions, which featured presentations by Frank Lagerwaard, M.D., from VU University Medical Center (VUmc) in Amsterdam, and Lorraine Portelance, M.D., from the University of Miami, Sylvester Comprehensive Cancer Center (University of Miami).

- Dr. Lagerwaard shared outcomes from VUmc's MRIdian program, which began patient treatments in May 2016. VUmc has treated patients for indications such as prostate SBRT, pancreas SBRT, liver metastases SBRT and moderately central lung tumors. The vast majority (96%) were treated using MRIdian's on-table adaptive therapy capabilities. A preliminary analysis of the dosimetric benefit of daily adaptive treatment for prostate cancer at VUmc shows clear benefits, avoiding both overdosage to the surrounding organs at risk such as bladder and rectum, while at the same time ensuring adequate planning target volume (PTV) coverage. VUmc has studies exploring MRIdian for inoperable pancreatic cancer and prostate cancer treated with 5 fraction SBRT, partial breast irradiation, early stage rectal cancer and moderately central lung tumors.

- Dr. Portelance shared outcomes from University of Miami's MRIdian program, which began patient treatments in April 2016. University of Miami has treated a variety of indications, including breast, bladder, cervical, liver, pancreatic, prostate and rectal cancers. MRIdian has become the University of Miami's preferred method for treating complex cancer cases that are difficult to treat on a standard RT system due to the location of the tumor in relation to the surrounding soft tissue, and has allowed them to treat a number of patients who would not previously have been considered RT candidates.

Rad Oncology Homepage